Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
France Targets Shein, Temu With Fast-Fashion Fees 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
OpenAI Rejects Apple Trade Secret Theft Claims 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Milei Threatens Falkland Oil Firms With Sanctions 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Add as a preferred source on Google
GAITHERSBURG, Md., March 07, 2018 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will provide a corporate update and report its fourth quarter and full year 2017 financial and operating results following the close of U.S. financial markets on Wednesday, March 14, 2018.
| Conference call and webcast details are as follows: | |
| Date: | March 14, 2018 |
| Time: | 5:00 p.m. U.S. Eastern Time (ET) |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) |
| Passcode: | 6472939 |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
| Conference call and webcast replay: | |
| Dates: | Starting at 8:00 p.m. ET, March 14, 2018 until |
| 9:00 p.m. ET March 21, 2018 | |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) |
| Passcode: | 6472939 |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until June 14, 2018 |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases. Our RSV and influenza nanoparticle vaccine candidates are Novavax’ most advanced clinical programs and are at the forefront of the Company’s efforts to improve global health. Additional information about Novavax is available on the Company's website, novavax.com.
Contact:
Investors
Westwicke Partners
John Woolford
[email protected]
443-213-0506
Media
Sam Brown
Mike Beyer
[email protected]
312-961-2502
